Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer.

Salvatore B, Caprio MG, Hill BS, Sarnella A, Roviello GN, Zannetti A.

Cancers (Basel). 2019 Oct 22;11(10). pii: E1614. doi: 10.3390/cancers11101614. Review.

2.

Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer.

Hill BS, Sarnella A, D'Avino G, Zannetti A.

Semin Cancer Biol. 2019 Aug 1. pii: S1044-579X(19)30211-1. doi: 10.1016/j.semcancer.2019.07.028. [Epub ahead of print] Review.

3.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N'Guyen S, Trager-Maury S, Chauvenet L, Abadie Lacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P.

Ann Oncol. 2019 May 1;30(5):845-852. doi: 10.1093/annonc/mdz074.

PMID:
30851097
4.

Therapeutic Potential of a Novel αvβ₃ Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type.

Hill BS, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M, Albanese S, Saviano M, Zaccaro L, Zannetti A.

Cancers (Basel). 2019 Jan 24;11(2). pii: E139. doi: 10.3390/cancers11020139.

5.

WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.

Cottin L, Riou J, Boyer F, Bouvier A, Zannetti A, Blouet A, Truchan-Graczyk M, Jouanneau-Courville R, Beucher A, Ribourtout B, Orvain C, Hunault-Berger M, Blanchet O, Ugo V, Luque Paz D.

Blood Cells Mol Dis. 2019 Mar;75:35-40. doi: 10.1016/j.bcmd.2018.12.004. Epub 2018 Dec 20.

PMID:
30612065
6.

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B.

Gynecol Oncol. 2019 Jan;152(1):68-75. doi: 10.1016/j.ygyno.2018.10.043. Epub 2018 Nov 14.

PMID:
30446275
7.

Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.

Camorani S, Hill BS, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L.

Theranostics. 2018 Oct 6;8(18):5178-5199. doi: 10.7150/thno.27798. eCollection 2018.

8.

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.

Camorani S, Fedele M, Zannetti A, Cerchia L.

Pharmaceuticals (Basel). 2018 Nov 13;11(4). pii: E123. doi: 10.3390/ph11040123. Review.

9.

Autocrine signals increase ovine mesenchymal stem cells migration through Aquaporin-1 and CXCR4 overexpression.

Pelagalli A, Nardelli A, Lucarelli E, Zannetti A, Brunetti A.

J Cell Physiol. 2018 Aug;233(8):6241-6249. doi: 10.1002/jcp.26493. Epub 2018 Mar 1.

PMID:
29345324
10.

Chemical Modification for Proteolytic Stabilization of the Selective αvβ3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells.

Comegna D, Zannetti A, Del Gatto A, de Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L.

J Med Chem. 2017 Dec 14;60(23):9874-9884. doi: 10.1021/acs.jmedchem.7b01590. Epub 2017 Dec 4.

PMID:
29144748
11.

Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype.

Hill BS, Pelagalli A, Passaro N, Zannetti A.

Oncotarget. 2017 Aug 14;8(42):73296-73311. doi: 10.18632/oncotarget.20265. eCollection 2017 Sep 22. Review.

12.

Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.

Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A.

Theranostics. 2017 Aug 22;7(14):3595-3607. doi: 10.7150/thno.18974. eCollection 2017.

13.

A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors.

Santagata S, Portella L, Napolitano M, Greco A, D'Alterio C, Barone MV, Luciano A, Gramanzini M, Auletta L, Arra C, Zannetti A, Scala S.

Sci Rep. 2017 May 31;7(1):2554. doi: 10.1038/s41598-017-02818-6.

14.

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.

Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, Denis F, Zinger M, Juhel-Voog L, Lafond C, Maillart P, Capitain O, Delva R, Soulié P, Abadie-Lacourtoisie S, Guérin-Meyer V, Morin-Meschin ME, Commer JM, Gangler A, d'Aillières B, Zannetti A, Bourbouloux E, Berton-Rigault D, Lebouvier-Sadot S, Kaassis M, Baudon J, Lam YH, Bizieux A, Marcq M, Edeline J, Le Du F, Lefeuvre C, Deguiral P, Delecroix V, Blot E, Egreteau J, Goudier MJ, Lamy R, Ferec M, Artignan X, Corbinais S, Morel H, Hardy-Bessard AC, Alleaume C, Naudeix E, Cojocarasu O, Metges JP, Riché C, Gamelin E, Déniel-Lagadec D, Marhuenda F, Ingrand P, Douillard JY.

Ann Oncol. 2017 Jul 1;28(7):1612-1617. doi: 10.1093/annonc/mdx172.

PMID:
28472235
15.

Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L.

Sci Rep. 2017 Apr 20;7:46659. doi: 10.1038/srep46659.

16.

Inhibition of AQP1 Hampers Osteosarcoma and Hepatocellular Carcinoma Progression Mediated by Bone Marrow-Derived Mesenchymal Stem Cells.

Pelagalli A, Nardelli A, Fontanella R, Zannetti A.

Int J Mol Sci. 2016 Jul 11;17(7). pii: E1102. doi: 10.3390/ijms17071102.

17.

High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma.

Greco A, Albanese S, Auletta L, Mirabelli P, Zannetti A, D'Alterio C, Di Maro G, Orlandella FM, Salvatore G, Soricelli A, Salvatore M.

Thyroid. 2016 Apr;26(4):552-8. doi: 10.1089/thy.2015.0511. Epub 2016 Mar 3.

PMID:
26844598
18.

Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT.

Gargiulo S, Anzilotti S, Coda AR, Gramanzini M, Greco A, Panico M, Vinciguerra A, Zannetti A, Vicidomini C, Dollé F, Pignataro G, Quarantelli M, Annunziato L, Brunetti A, Salvatore M, Pappatà S.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1348-59. doi: 10.1007/s00259-016-3311-y. Epub 2016 Jan 27.

PMID:
26816193
19.

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ieranò C, Cerchia L, Lucarelli E, Scala S, Zannetti A.

Cancer Lett. 2016 Jan 1;370(1):100-7. doi: 10.1016/j.canlet.2015.10.018. Epub 2015 Oct 27.

PMID:
26517945
20.

Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.

Greco A, Zannetti A, Pappatà S, Albanese S, Coda AR, Ragucci M, Nardelli A, Brunetti A, Cuocolo A, Salvatore M.

Q J Nucl Med Mol Imaging. 2018 Mar;62(1):112-117. doi: 10.23736/S1824-4785.17.02813-8. Epub 2015 Sep 1.

PMID:
26329495
21.

In vivo imaging and characterization of [(18)F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET.

Vicidomini C, Panico M, Greco A, Gargiulo S, Coda AR, Zannetti A, Gramanzini M, Roviello GN, Quarantelli M, Alfano B, Tavitian B, Dollé F, Salvatore M, Brunetti A, Pappatà S.

Nucl Med Biol. 2015 Mar;42(3):309-16. doi: 10.1016/j.nucmedbio.2014.11.009. Epub 2014 Dec 6.

PMID:
25537727
22.

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R.

Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19.

23.

3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S.

J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.

24.

PET/CT in cancer research: from preclinical to clinical applications.

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M.

Contrast Media Mol Imaging. 2010 Jul-Aug;5(4):190-200. doi: 10.1002/cmmi.368. Review.

PMID:
20812287
25.

Molecular imaging of tumor microenvironment: challenges and perspectives.

Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M.

Q J Nucl Med Mol Imaging. 2010 Jun;54(3):249-58. Review.

PMID:
20639812
26.

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.

BJU Int. 2010 Oct;106(7):974-8. doi: 10.1111/j.1464-410X.2010.09296.x. Epub 2010 Mar 9.

27.

Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.

Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, de Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, de Franciscis V.

Oncology. 2009;77(6):378-84. doi: 10.1159/000276765. Epub 2010 Jan 18.

PMID:
20090381
28.

Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).

Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M.

Clin Cancer Res. 2009 Aug 15;15(16):5224-33. doi: 10.1158/1078-0432.CCR-08-3270. Epub 2009 Aug 11.

29.

A new and selective radiolabeled alphavbeta3 peptide antagonist as tracer in tumor diagnosis.

De Luca S, Del Gatto A, Ruvo M, Panico MR, Zannetti A, Del Vecchio S, Salvatore M, Pedone C, Saviano M, Zaccaro L.

Adv Exp Med Biol. 2009;611:439-40. No abstract available.

PMID:
19400256
30.

Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.

Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S.

Clin Cancer Res. 2008 Aug 15;14(16):5209-19. doi: 10.1158/1078-0432.CCR-08-0374.

31.

Functional imaging of multidrug resistance in breast cancer.

Vecchio SD, Zannetti A, Salvatore B, Paone G, Fonti R, Salvatore M.

Phys Med. 2006;21 Suppl 1:24-7.

PMID:
17645989
32.

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, Gomez P, Paule B, Genet D, Hérait P, Ecstein-Fraïssé E, Joly F.

Ann Oncol. 2007 Jun;18(6):1064-70. Epub 2007 Apr 13.

PMID:
17434899
33.

Nuclear imaging in cancer theranostics.

Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M.

Q J Nucl Med Mol Imaging. 2007 Jun;51(2):152-63. Review.

34.

Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.

Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M.

J Med Chem. 2006 Jun 1;49(11):3416-20.

PMID:
16722662
35.

Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.

Zannetti A, Del Vecchio S, Romanelli A, Scala S, Saviano M, Cali' G, Stoppelli MP, Pedone C, Salvatore M.

Biochem Pharmacol. 2005 Nov 1;70(9):1277-87.

PMID:
16143315
36.

Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma.

Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Catalano L, Pace L, Rotoli B, Salvatore M.

Cancer Biother Radiopharm. 2004 Apr;19(2):165-70.

PMID:
15186596
37.

In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.

Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M.

J Nucl Med. 2004 Mar;45(3):485-94.

38.

Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines.

Aloj L, Zannetti A, Caracó C, Del Vecchio S, Salvatore M.

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):521-7. Epub 2003 Dec 10.

PMID:
14666386
39.

Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.

Del Vecchio S, Zannetti A, Aloj L, Caracò C, Ciarmiello A, Salvatore M.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):879-87. Epub 2003 Apr 30.

PMID:
12721767
40.

MIBI as prognostic factor in breast cancer.

Del Vecchio S, Zannetti A, Aloj L, Salvatore M.

Q J Nucl Med. 2003 Mar;47(1):46-50. Review.

41.

Radiolabeling approaches for cholecystokinin B receptor imaging.

Aloj L, Panico MR, Caracó C, Zannetti A, Del Vecchio S, Di Nuzzo C, Arra C, Morelli G, Tesauro D, De Luca S, Pedone C, Salvatore M.

Biopolymers. 2002;66(6):370-80. Review.

PMID:
12658724
42.

Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients.

Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):809-14. Epub 2002 Mar 13.

PMID:
12029556
43.

Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma.

Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M.

Eur J Nucl Med. 2001 Feb;28(2):214-20.

PMID:
11303893
44.

Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.

Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 2000 Mar 15;60(6):1546-51.

45.

Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.

Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP.

Cancer Res. 1999 Oct 15;59(20):5307-14.

46.

Dual modulation of Na/H antiport by atrial natriuretic factor in rat aortic smooth muscle cells.

Ricci R, Baldini P, Bogetto L, De Vito P, Luly P, Zannetti A, Incerpi S.

Am J Physiol. 1997 Aug;273(2 Pt 1):C643-52.

PMID:
9277362
48.

Selective activation by atrial natriuretic factor of phosphatidylcholine-specific phospholipase activities in purified heart muscle plasma membranes.

Baldini PM, Incerpi S, Zannetti A, De Vito P, Luly P.

J Mol Cell Cardiol. 1994 Dec;26(12):1691-700.

PMID:
7731062
49.

Insulin-stimulated hydrolysis of phosphatidylcholine by phospholipase C and phospholipase D in cultured rat hepatocytes.

Donchenko V, Zannetti A, Baldini PM.

Biochim Biophys Acta. 1994 Jul 21;1222(3):492-500.

PMID:
8038220
50.

Modulation of the Na-H antiport by insulin: interplay between protein kinase C, tyrosine kinase, and protein phosphatases.

Incerpi S, Baldini P, Bellucci V, Zannetti A, Luly P.

J Cell Physiol. 1994 May;159(2):205-12.

PMID:
8163561

Supplemental Content

Loading ...
Support Center